Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa.
The prototype virus HIV-1 LAV and highly cytopathic Zairian virus HIV-1 NDK belong to the genetic subtypes B and D and represent low and highly cytopathic phenotypes, respectively. Their neutralization pattern and serotype were studied with respect to differences in their genotypes and phenotypes. Sera from HIV-1-infected persons living in four geographically distant areas, Philadelphia (USA), Ribeirao Preto (Brazil), Marseille (France) and Kinshasa (Zaire), were tested for the presence of type-specific and group-specific cross-reacting neutralizing antibodies against HIV-1 LAV and HIV-1 NDK in a continuous cell line MT4. The majority of type-specific antibodies were directed against HIV-1 LAV in Philadelphia, Ribeirao Preto and Marseille, and against HIV-1 NDK in Kinshasa. However, some sera with an HIV-1 NDK type-specific neutralization pattern were also found in Philadelphia, Ribeirao Preto and Marseille. These results indicate that strains with an HIV-1 NDK-like serotype could be found outside Africa. The presence of type-specific neutralizing antibodies against HIV-1 NDK in sera from North and South America and Europe should be taken into account during attempts to serotype HIV as well as in the course of selection of HIV-1 candidate strains for an AIDS vaccine.
Machado
A A
AA
INSERM U322, Unité de Recherches sur les Rétrovirus et Maladies, Associées, Marseille, France.
Bakpabua
M
M
Salaun
D
D
de Mareuil
J
J
Krchnak
V
V
MacGregor
R R
RR
Chermann
J C
JC
Hirsch
I
I
D000595:Amino Acid Sequence; D000918:Antibody Specificity; D001938:Brazil / Q000453:epidemiology; D015023:Democratic Republic of the Congo / Q000453:epidemiology; D005602:France / Q000453:epidemiology; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000453:epidemiology* / Q000276:immunology*; D006679:HIV Seropositivity / Q000453:epidemiology / Q000276:immunology; D015497:HIV-1 / Q000145:classification* / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D015994:Incidence; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D015995:Prevalence; D014481:United States / Q000453:epidemiology
D015483:HIV Antibodies